The Specialized Histopathology Core was first approved and funded through the CCSG mechanism in 2005. The Core delivers services in a timely fashion and provides the geographically dispersed Cancer Center members with appropriate access to pathology consultative and interpretive services. There are two performance sites: Longwood (which is within minutes of six of the member institutions) and MGH, based at Massachusetts General Hospital. These two locations have enabled the Core to continue to grow and improve service delivery by increasing overall capacity, space and affiliated professional expertise. A full understanding of cancer pathogenesis and response to therapies requires access to technologies and professional expertise that allow cancer cells and biomarkers to be analyzed in situ. The Specialized Histopathology Services (SHP) Core meets this need by providing technical and professional pathology services to Dana-Farber/Harvard Cancer Center (DF/HCC) investigators conducting research with experimental organisms (e.g., rodents, fish, and monkeys) or human tissues. This facility also assists with experimental design and data interpretation. Director(s): Jon Aster, MD, PhD(BMW), Anat Stemmer-Rachamimov, MD(MGH) Category: 4.06 (Human Tissue Acquisition &Pathology/Histology) Management: Joint (Cancer Center and Institutional)
The facility contributes to the scientific mission of the Cancer Center by supporting a wide spectrum of cancer-relevant research, from basic studies on pathogenic mechanisms in cancer to translational research focused on the development of new tests for biomarkers that stratify patients and direct therapy.
| Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945 |
| Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37: |
| Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534 |
| Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583 |
| Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404 |
| Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917 |
| Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121 |
| Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538 |
| Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228 |
| Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609 |
Showing the most recent 10 out of 411 publications
